{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:40:46Z","timestamp":1793014846561,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001835","name":"Universiteit Maastricht","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001835","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jval.2024.07.009","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T12:57:41Z","timestamp":1722430661000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer\u2019s Disease Treatment: Development and Use Cases"],"prefix":"10.1016","volume":"28","author":[{"given":"Ron","family":"Handels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Herring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Sk\u00f6ldunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2024.07.009_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2024.07.009_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2024.07.009_bib6","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint","volume":"29","author":"J\u00f6nsson","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jval.2024.07.009_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6963-14-2","article-title":"A\u00a0systematic review of barriers to and facilitators of the use of evidence by policymakers","volume":"14","author":"Oliver","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.jval.2024.07.009_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jval.2021.10.001","article-title":"Open source models special interest G. Opportunities and barriers to the development and use of open source health economic models: a survey","volume":"25","author":"Pouwels","year":"2022","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2024.07.009_bib9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40273-019-00819-z","article-title":"Transparency in decision modelling: what, why, who and how?","volume":"37","author":"Sampson","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2024.07.009_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Force I-SMGRPT. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2024.07.009_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jalz.2019.05.004","article-title":"Assessing cost-effectiveness of early intervention in Alzheimer\u2019s disease: an open-source modeling framework","volume":"15","author":"Green","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.jval.2024.07.009_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40273-022-01131-z","article-title":"Assessments of the value of new interventions should include health equity impact","volume":"40","author":"Jansen","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2024.07.009_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2174\/1567205017666201203121907","article-title":"How much value would a treatment for Alzheimer\u2019s disease offer? Cost-effectiveness thresholds for pricing a disease-modifying therapy","volume":"17","author":"Jun","year":"2020","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.1016\/j.jval.2024.07.009_bib14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer\u2019s disease","volume":"10","author":"Herring","year":"2021","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.jval.2024.07.009_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","article-title":"Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US","volume":"79","author":"Ross","year":"2022","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.jval.2024.07.009_bib16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/alz.12811","article-title":"Cost-effectiveness models for Alzheimer\u2019s disease and related dementias: IPECAD modeling workshop cross-comparison challenge","volume":"19","author":"Handels","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.jval.2024.07.009_bib17","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/j.jval.2023.09.2194","article-title":"MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer\u2019s Disease and Related Dementias","volume":"26","author":"Handels","year":"2023","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2024.07.009_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jalz.2008.02.003","article-title":"Decision analytic models for Alzheimer\u2019s disease: state of the art and future directions","volume":"4","author":"Cohen","year":"2008","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.jval.2024.07.009_bib19","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1017\/S1041610218001291","article-title":"Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment","volume":"30","author":"Nguyen","year":"2018","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.jval.2024.07.009_bib20","article-title":"Health economic modeling for Alzheimer\u2019s disease: expert perspectives","volume":"8","author":"Landeiro","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.1016\/j.jval.2024.07.009_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40258-024-00878-0","article-title":"Model-based economic evaluations of interventions for dementia: an updated systematic review and quality assessment","volume":"22","author":"Darab","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2024.07.009_bib22","author":"Lin"},{"issue":"3","key":"10.1016\/j.jval.2024.07.009_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40120-023-00460-1","article-title":"Estimated societal value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"12","author":"Tahami Monfared","year":"2023","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.jval.2024.07.009_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-191055","article-title":"Quantifying and describing the natural history and costs of Alzheimer\u2019s disease and effects of hypothetical interventions","volume":"75","author":"Wimo","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.jval.2024.07.009_bib25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/archneurol.2010.115","article-title":"Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer\u2019s coordinating center database","volume":"67","author":"O\u2019Bryant","year":"2010","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.jval.2024.07.009_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s40120-021-00272-1","article-title":"Estimating progression rates across the spectrum of Alzheimer\u2019s disease for amyloid-positive individuals using national Alzheimer\u2019s coordinating center data","volume":"10","author":"Potashman","year":"2021","journal-title":"Neurol Ther"},{"issue":"8","key":"10.1016\/j.jval.2024.07.009_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1567205015666180119092427","article-title":"Estimating Alzheimer\u2019s disease progression rates from normal cognition through mild cognitive impairment and stages of dementia","volume":"15","author":"Davis","year":"2018","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.1016\/j.jval.2024.07.009_bib28","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/alz.13488","article-title":"Predicting sojourn times across dementia disease stages, institutionalization, and mortality","volume":"20","author":"Tate","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"11","key":"10.1016\/j.jval.2024.07.009_bib29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","article-title":"Estimating transition probabilities from published evidence: a tutorial for decision Modelers","volume":"38","author":"Gidwani","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2024.07.009_bib30","first-page":"1078","article-title":"The effectiveness and value of lecanemab for early Alzheimer disease: a summary from the Institute for Clinical and Economic Review\u2019s California Technology Assessment Forum","volume":"29","author":"Wright","year":"2023","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jval.2024.07.009_bib31","article-title":"Aducanumab for Alzheimer\u2019s disease: effectiveness and value; Final evidence report and meeting summary","author":"Lin","year":"2021","journal-title":"Institute for Clinical and Economic Review"},{"issue":"9","key":"10.1016\/j.jval.2024.07.009_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1212\/WNL.0000000000013313","article-title":"Performing cost-effectiveness analyses to support policy making: key lessons from the assessment of aducanumab","volume":"98","author":"Campbell","year":"2022","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jval.2024.07.009_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1212\/WNL.52.6.1138","article-title":"Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer\u2019s disease","volume":"52","author":"Neumann","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jval.2024.07.009_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.trci.2018.01.001","article-title":"Alzheimer\u2019s disease Archimedes condition-event simulator: development and validation","volume":"4","author":"Kansal","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.1016\/j.jval.2024.07.009_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40120-022-00350-y","article-title":"Long-term health outcomes of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.jval.2024.07.009_bib36","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","article-title":"The potential economic value of lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.jval.2024.07.009_bib37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/11531870-000000000-00000","article-title":"Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer\u2019s disease: a UK evaluation using discrete-event simulation","volume":"28","author":"Getsios","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2024.07.009_bib38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/brain\/awv029","article-title":"Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage","volume":"138","author":"Vos","year":"2015","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.jval.2024.07.009_bib39","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s40273-019-00837-x","article-title":"A\u00a0need for change! A coding framework for improving transparency in decision modeling","volume":"37","author":"Alarid-Escudero","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.07.009_bib40","author":"Alarid-Escudero"},{"issue":"1","key":"10.1016\/j.jval.2024.07.009_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0272989X221103163","article-title":"An introductory tutorial on cohort state-transition models in R using a cost-effectiveness analysis example","volume":"43","author":"Alarid-Escudero","year":"2023","journal-title":"Med Decis Mak"},{"issue":"9","key":"10.1016\/j.jval.2024.07.009_bib42","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1212\/WNL.0000000000013314","article-title":"Cost-effectiveness and value-based pricing of aducanumab for patients with early Alzheimer disease","volume":"98","author":"Whittington","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jval.2024.07.009_bib43","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40120-023-00492-7","article-title":"Predicting the societal value of lecanemab in early Alzheimer\u2019s disease in Japan: a patient-level simulation","volume":"12","author":"Igarashi","year":"2023","journal-title":"Neurol Ther"},{"issue":"6","key":"10.1016\/j.jval.2024.07.009_bib44","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jval.2020.01.010","article-title":"Application of discrete-event simulation in health technology assessment: a cost-effectiveness analysis of Alzheimer\u2019s disease treatment using real-world evidence in Thailand","volume":"23","author":"Kongpakwattana","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2024.07.009_bib45","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.clinthera.2022.09.008","article-title":"Assessing the cost-effectiveness of a hypothetical disease-modifying therapy with limited duration for the treatment of early symptomatic Alzheimer disease","volume":"44","author":"Boustani","year":"2022","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.jval.2024.07.009_bib46","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209218","article-title":"Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease","volume":"102","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jval.2024.07.009_bib47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.14283\/jpad.2024.67","article-title":"Optimising Alzheimer\u2019s disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment","volume":"11","author":"Aye","year":"2024","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"8","key":"10.1016\/j.jval.2024.07.009_bib48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jalz.2015.02.009","article-title":"Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer\u2019s disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment","volume":"11","author":"Handels","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.jval.2024.07.009_bib49","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/joim.13759","article-title":"People get ready! A new generation of Alzheimer\u2019s therapies may require new ways to deliver and pay for healthcare","volume":"295","author":"Wahlberg","year":"2024","journal-title":"J\u00a0Intern Med"},{"issue":"8","key":"10.1016\/j.jval.2024.07.009_bib50","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1002\/alz.13001","article-title":"The value of maintaining cognition in patients with mild cognitive impairment: the innovation headroom and potential cost-effectiveness of Roflumilast","volume":"19","author":"Handels","year":"2023","journal-title":"Alzheimers Dement"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:15:51Z","timestamp":1743012951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1098301524027906"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.009","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.05.24305373","asserted-by":"object"}]},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer\u2019s Disease Treatment: Development and Use Cases","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}